drugset
drugset / Trial / NCT03806478

Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease

NCT03806478 ↗

Phase 2 Unknown 60 enrolled Aphios
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.

Timeline

Start
2023-06
Primary completion
2024-09
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject APH-1105 Unknown 0.5 ug Intranasal
Subject APH-1105 Unknown 1 ug Intranasal
Subject APH-1105 Unknown 2 ug Intranasal

Indications

Alzheimer disease 2 Alzheimer disease 3 Alzheimer disease type 1